Prime Time for a Trial Assessing Safety of Intravenous Thrombolysis in Patients Treated With Direct Oral Anticoagulants

Stroke. 2024 Jun;55(6):e149-e150. doi: 10.1161/STROKEAHA.123.046142. Epub 2024 Apr 26.

Authors

Christian Boehme¹, Lukas Mayer-Suess¹, Dominika Mikšová², Wilfried Lang^{3

4}, Michael Knoflach^{1

4}, Stefan Kiechl^{1

4}; Austrian Stroke Unit Registry Collaborators

Affiliations

¹ Department of Neurology, Medical University of Innsbruck, Austria (C.B., L.M.-S., M.K., S.K.).
² Austrian National Public Health Institute (Gesundheit Osterreich GmbH)/The Austrian National Institute for Quality in Health, Vienna, Austria (D.M.).
³ Medical Faculty, Sigmund Freud Private University, Vienna, Austria (W.L.).
⁴ VASCage-Research Centre on Vascular Ageing and Stroke, Innsbruck, Austria (W.L., M.K., S.K.).

PMID: 38666383
DOI: 10.1161/STROKEAHA.123.046142

No abstract available

Keywords: anticoagulants; mortality; patients; randomized controlled trial; stroke.

Publication types

Letter

MeSH terms

Administration, Intravenous
Administration, Oral
Anticoagulants* / administration & dosage
Anticoagulants* / adverse effects
Anticoagulants* / therapeutic use
Fibrinolytic Agents / administration & dosage
Fibrinolytic Agents / adverse effects
Fibrinolytic Agents / therapeutic use
Humans
Ischemic Stroke / drug therapy
Stroke / drug therapy
Thrombolytic Therapy* / adverse effects
Thrombolytic Therapy* / methods

Substances

Anticoagulants
Fibrinolytic Agents